While many advocacy groups set out to raise money for cancer research, a first-of-its-kind charitable crowdfunding platform, called Sound Affects, has set out to change how the war on cancer is fought and financed, all with support from musical talents.
I know my life will never be the same again. I will not ever be well or free of chemo and treatments and shots and blood counts and bone marrow biopsies. I have slowly become used to my new way of life.
Fueled by the tragic loss of their son, Tony and his wife Vicky Martell built the foundation by working closely with their passionate friends in the music industry to continue his legacy and expand the foundation’s fundraising initiatives every year.
Sometimes breast cancer warriors need subtle reminders of their courageous fight. One survivor received that message from a coffee mug.
When diagnosing patients with multiple myeloma, it is important to identify the specific stage, mutations and risk level of the disease to determine the most effective treatment method, according to Jeffrey Wolf, M.D.
There are now three PARP inhibitors approved for the treatment of ovarian cancer, improving outcomes of many of the women who take them.
In April 2017, I thought I felt a new mass in my remaining testicle, but it ended up being clear. In May 2018, it happened again... but this time, it was different.
How two crazy uncles have helped me through my battles with cancer, and eventually faced battles of their own.
Paradigms are shifting in the way that ovarian cancer is being treated.
The science behind immunotherapy and gastrointestinal cancers is not quite perfected yet, but one subset of patients is seeing remarkable results.
Written by a breast cancer survivor, a book I recently read is still applicable to me as a testicular cancer survivor.
The Food and Drug Administration (FDA) has granted a priority review to a new drug application (NDA) for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia (AML), according to Astellas Pharma, the manufacturer of the FLT3 inhibitor.
The FDA has granted a priority review to a new drug application (NDA) for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with an NTRK gene fusion, according to Bayer and Loxo Oncology, the codevelopers of the pan-TRK inhibitor.
How even "Indiana Jones" can remind a survivor of medical procedures from years ago.
It seems there are apps for everything under the sun, but did you know there are many health-related apps for our phones that might be beneficial to you?
A rudimentary knowledge of the alphabet is one of the first things a school aged child learns, but sometimes, adults need a refresher course, especially when choosing a prosthesis.
An Extraordinary Healer essay honoring JACKIE MILLER, B.S.N., RN, OCN [PENN MEDICINE VIRTUA CANCER PROGRAM, VOORHEES, NEW JERSEY]
Memorial Day has multiple meanings for this cancer survivor.
Communication between health care professionals and institutions can be vital to ensure the best treatment possible.
This is what surviving cancer sounds like.
NCCN guidelines recommend annual mammograms to detect disease recurrence, but according to the study’s findings, women — even those who had adequate health insurance — were less likely to have their once-a-year mammogram as they became long-term survivors.
Despite improved outcomes, the researchers also found that side effects with checkpoint inhibition often affected the dermatologic, gastrointestinal, pulmonary, renal, endocrine and hepatic systems in patients.
It can feel like you're running out of time to get it right, says this patient with metastatic breast cancer.
Once you have experienced cancer, you can take those learnings and help others when trauma hits in their lives.
Planting a tree can be a wonderful and lasting way to honor a survivor or a loved one who has passed.
Genetic testing is becoming more important in pancreatic cancer, especially since it can point toward more efficacious treatment regimens for some patients.
PD-1 and PD-L1 inhibitors are generally well-tolerated, so most patients face little or no issues with the drugs. However, there are still some things to look out for.
A male breast cancer survivor reveals some startling statistics.
The Food and Drug Administration (FDA) approved a new formulation of Yonsa (abiraterone acetate) in combination with methylprednisolone as a treatment for men with metastatic castration-resistant prostate cancer (mCRPC), according to Sun Pharma, the company commercializing the treatment.
Cancer survivors worry about recurrence, but seldom think about their risk for new primaries.
